Lipocine (NASDAQ:LPCN) Cut to Sell at Wall Street Zen

Lipocine (NASDAQ:LPCN) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Several other research firms also recently issued reports on LPCN. Weiss Ratings restated a “sell (d-)” rating on shares of Lipocine in a report on Monday, December 29th. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price (up from $7.00) on shares of Lipocine in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Lipocine currently has a consensus rating of “Moderate Buy” and an average target price of $15.00.

Lipocine Trading Down 8.8%

LPCN opened at $7.34 on Friday. The business has a 50 day moving average of $9.08 and a 200-day moving average of $5.34. The stock has a market capitalization of $40.75 million, a price-to-earnings ratio of -4.35 and a beta of 0.98. Lipocine has a 1-year low of $2.52 and a 1-year high of $12.37.

Lipocine (NASDAQ:LPCN) last announced its earnings results on Monday, March 9th. The specialty pharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.26. The business had revenue of $1.15 million for the quarter, compared to analyst estimates of $0.12 million. Lipocine had a negative net margin of 487.00% and a negative return on equity of 59.30%.

Institutional Investors Weigh In On Lipocine

Institutional investors and hedge funds have recently bought and sold shares of the business. Citadel Advisors LLC acquired a new position in shares of Lipocine in the 3rd quarter valued at $41,000. Jane Street Group LLC acquired a new stake in shares of Lipocine during the 4th quarter valued at about $85,000. Renaissance Technologies LLC boosted its position in shares of Lipocine by 3.6% during the 4th quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock valued at $300,000 after acquiring an additional 1,300 shares in the last quarter. Boothbay Fund Management LLC bought a new stake in Lipocine in the fourth quarter valued at about $441,000. Finally, Geode Capital Management LLC raised its position in Lipocine by 2.2% in the fourth quarter. Geode Capital Management LLC now owns 62,450 shares of the specialty pharmaceutical company’s stock worth $502,000 after purchasing an additional 1,374 shares in the last quarter. Institutional investors own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.